BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 19460858)

  • 1. Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro.
    Frigo DE; Sherk AB; Wittmann BM; Norris JD; Wang Q; Joseph JD; Toner AP; Brown M; McDonnell DP
    Mol Endocrinol; 2009 Sep; 23(9):1385-96. PubMed ID: 19460858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor and chemokine receptors 4 and 7 form a signaling axis to regulate CXCL12-dependent cellular motility.
    Hsiao JJ; Ng BH; Smits MM; Wang J; Jasavala RJ; Martinez HD; Lee J; Alston JJ; Misonou H; Trimmer JS; Wright ME
    BMC Cancer; 2015 Mar; 15():204. PubMed ID: 25884570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor.
    Kasina S; Macoska JA
    Mol Cell Endocrinol; 2012 Apr; 351(2):249-63. PubMed ID: 22245379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of CXC-motif chemokine receptor 7, but not 4, expression is related to migration of the human prostate cancer cell LNCaP: regulation by androgen and inflammatory stimuli.
    Yu L; Pham Q; Yu LL; Wang TTY
    Inflamm Res; 2020 Feb; 69(2):167-178. PubMed ID: 31865399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen Triggers the Pro-Migratory CXCL12/CXCR4 Axis in AR-Positive Breast Cancer Cell Lines: Underlying Mechanism and Possible Implications for the Use of Aromatase Inhibitors in Breast Cancer.
    Azariadis K; Kiagiadaki F; Pelekanou V; Bempi V; Alexakis K; Kampa M; Tsapis A; Castanas E; Notas G
    Cell Physiol Biochem; 2017; 44(1):66-84. PubMed ID: 29131020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol inhibits DHT-induced progression of prostate cancer cell line through interfering with the AR and CXCR4 pathway.
    Jang YG; Go RE; Hwang KA; Choi KC
    J Steroid Biochem Mol Biol; 2019 Sep; 192():105406. PubMed ID: 31185279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis.
    Arya M; Patel HR; McGurk C; Tatoud R; Klocker H; Masters J; Williamson M
    J Exp Ther Oncol; 2004 Dec; 4(4):291-303. PubMed ID: 15844659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SLUG promotes prostate cancer cell migration and invasion via CXCR4/CXCL12 axis.
    Uygur B; Wu WS
    Mol Cancer; 2011 Nov; 10():139. PubMed ID: 22074556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
    Zhu WB; Zhao ZF; Zhou X
    J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion.
    Singh S; Singh UP; Grizzle WE; Lillard JW
    Lab Invest; 2004 Dec; 84(12):1666-76. PubMed ID: 15467730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proinflammatory CXCL12-CXCR4/CXCR7 Signaling Axis Drives Myc-Induced Prostate Cancer in Obese Mice.
    Saha A; Ahn S; Blando J; Su F; Kolonin MG; DiGiovanni J
    Cancer Res; 2017 Sep; 77(18):5158-5168. PubMed ID: 28687617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor negatively influences the expression of chemokine receptors (CXCR4, CCR1) and ligand-mediated migration in prostate cancer DU-145.
    Akashi T; Koizumi K; Nagakawa O; Fuse H; Saiki I
    Oncol Rep; 2006 Oct; 16(4):831-6. PubMed ID: 16969502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN loss mediated Akt activation promotes prostate tumor growth and metastasis via CXCL12/CXCR4 signaling.
    Conley-LaComb MK; Saliganan A; Kandagatla P; Chen YQ; Cher ML; Chinni SR
    Mol Cancer; 2013 Jul; 12(1):85. PubMed ID: 23902739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome proliferator‑activated receptor γ agonist rosiglitazone inhibits migration and invasion of prostate cancer cells through inhibition of the CXCR4/CXCL12 axis.
    Qin L; Gong C; Chen AM; Guo FJ; Xu F; Ren Y; Liao H
    Mol Med Rep; 2014 Aug; 10(2):695-700. PubMed ID: 24842333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model.
    Shanmugam MK; Manu KA; Ong TH; Ramachandran L; Surana R; Bist P; Lim LH; Kumar AP; Hui KM; Sethi G
    Int J Cancer; 2011 Oct; 129(7):1552-63. PubMed ID: 21480220
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism.
    Poluri RTK; Paquette V; Allain ÉP; Lafront C; Joly-Beauparlant C; Weidmann C; Droit A; Guillemette C; Pelletier M; Audet-Walsh É
    Endocr Relat Cancer; 2021 Apr; 28(4):257-271. PubMed ID: 33690159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
    Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
    Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
    Dulinska-Litewka J; McCubrey JA; Laidler P
    Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer.
    Zhang S; Qi L; Li M; Zhang D; Xu S; Wang N; Sun B
    J Exp Clin Cancer Res; 2008 Nov; 27(1):62. PubMed ID: 18983683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
    Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
    Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.